Form 4: LAVA Therapeutics CFO Sells Shares, Options

LAVA Therapeutics NV's Chief Financial Officer, Fred M. Powell, disposed of 65,000 common shares and cancelled 124,700 share options as part of a pre-arranged purchase agreement.

Summary

• Fred M. Powell, Chief Financial Officer of LAVA Therapeutics NV (LVTX), reported a change in beneficial ownership.
• On November 13, 2025, Mr. Powell disposed of 65,000 common shares.
• On the same date, 124,700 share options with an exercise price of $0.93 were cancelled.
• These transactions were executed pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• The common shares were exchanged for $1.04 in cash per share and one non-transferable contingent value right (CVR) per share.
• The share options were cancelled in exchange for a cash amount equal to the excess of $1.04 over the $0.93 exercise price per share, multiplied by the total number of shares underlying the option, plus one CVR per share.
• Following these reported transactions, Fred M. Powell holds 0 common shares and 0 derivative securities directly.

Sentiment

Score: 4

Explanation: The complete divestment of direct holdings by a Chief Financial Officer can be viewed negatively by the market, suggesting a lack of long-term commitment or a belief that the current valuation is fair or even high. However, the transaction is part of a larger Purchase Agreement, which might have strategic benefits for the company, and the CVRs offer potential future value, making the overall sentiment mixed but leaning cautious.

Positives

• The transaction provides liquidity to the Chief Financial Officer through a cash component for both shares and options.
• The inclusion of Contingent Value Rights (CVRs) offers potential future value to the disposed securities, contingent on specific future events or milestones.

Negatives

• The complete divestment of direct beneficial ownership in common shares and derivative securities by a key executive (CFO) could be perceived negatively by the market, potentially signaling a lack of long-term confidence.
• The reporting person no longer holds any direct equity stake in the company following these transactions.

Risks

• Potential negative market reaction to the complete divestment of direct holdings by a Chief Financial Officer, which could impact the company's share price.
• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events, introducing an element of risk to the overall consideration received.

Future Outlook

The filing details a pre-arranged insider transaction and does not provide explicit forward-looking statements or guidance from the company. However, the inclusion of Contingent Value Rights (CVRs) implies potential future payments tied to specific, undisclosed future events or milestones for LAVA Therapeutics NV.

Industry Context

This Form 4 filing reports an insider transaction by a key executive in the biotechnology sector. While not providing direct industry context, such a significant divestment by a CFO can be interpreted by the market in the context of broader industry trends or company-specific prospects. The involvement of XOMA Royalty Corporation in the Purchase Agreement suggests a strategic transaction, potentially related to intellectual property monetization or a financing event, which is common in the biotech industry.

Comparison to Industry Standards

• This is an insider transaction report, not a financial performance report, so direct comparison to industry financial benchmarks is not applicable.
• Insider selling, particularly a complete divestment by a CFO, is a significant event that is often scrutinized more closely than routine sales, especially when compared to executive compensation and divestment strategies within the biotech/pharma sector.

Related Party Transactions

• Disposal of 65,000 common shares and cancellation of 124,700 share options by Fred M. Powell, Chief Financial Officer, to the issuer (LAVA Therapeutics NV) as part of a Purchase Agreement with XOMA Royalty Corporation. This constitutes an insider transaction.

Stakeholder Impact

• Shareholders: May react negatively to a key executive's complete divestment of direct holdings, potentially impacting share price. The CVRs could offer future value depending on their terms and the success of underlying events.
• Management/Employees: The CFO's personal financial decision might influence morale or perception within the company regarding leadership's long-term commitment.

Key Dates

Recommendation

While the complete divestment of direct holdings by the CFO could be a negative signal, the transaction is part of a larger Purchase Agreement with XOMA Royalty Corporation, which might have strategic implications not fully detailed in this Form 4. The inclusion of Contingent Value Rights (CVRs) suggests potential future value tied to specific events. Without further details on the underlying Purchase Agreement and the terms of the CVRs, a 'hold' recommendation is prudent, awaiting more comprehensive information on the company's strategic direction and the full context of this transaction.

Keywords

LAVA Therapeutics NV, LVTX, Form 4, Insider Transaction, CFO, Share Disposal, Option Cancellation, Contingent Value Right, XOMA Royalty Corporation, Rule 10b5-1